Board of Directors

The Board of Directors, comprised of leading asthma experts, is GINA’s main governing body. It encourages dissemination and adoption of the reports on asthma management through utilization of existing health care structures in individual countries and promotes international collaboration on asthma research.

The GINA Board of Directors meets several times a year to discuss and plan programs and activities to carry out the goals of the GINA program.


Louis-Philippe Boulet MD, chair
Laval University and Quebec Heart and Lung Institute
2725 Chemin Sainte-Foy
Sainte-Foy (Quebec) G1V 4G5 Canada

Keith Allan, CBiol, MRSB
Patient Partner
University Hospitals of Leicester LE1 5WW, UK

Eric D. Bateman, MD
University Cape Town Lung Institute
George Street
Mowbray, 7700
Cape Town, South Africa

Guy Brusselle, MD, PhD, FERS
Department of Respiratory Medicine
Ghent University Hospital
B-9000 Ghent

Muhwa Jeremiah Chakaya, MD
Respiratory Society of Kenya

Alvaro A. Cruz, MD
Federal University of Bahia
School of Medicine
Av. Sta. Luzia, 379 ap. 1501 - OB
40295-050 Salvador - BA, Brazil

Hiromasa Inoue, MD
Department of Pulmonary Medicine Kagoshima University
Kagoshima 890-8520, Japan

Jerry A. Krishnan, MD, PhD
Division of Pulmonary, Critical Care, Sleep, and Allergy
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 60612

Mark L. Levy, MD
General Practitioner

Helen K. Reddel, MBBS, PhD
Woolcock Institute of Medical Research
PO Box M77 Missenden Road
Camperdown, NSW 2050, Australia

Arzu Yorgancioglu, MD
Celal Bayar University
Department of Pulmonology
Manisa, Turkey

Updated October 2022

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations in December of each year using the following definitions:

  • Personal Benefits (Consultancy-Lecture Fees) refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
  • Shares refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
  • Non-Personal Interests refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

View Board and Committee Annual Disclosures